Clinical Trial Update: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a darunavir/cobicistat/emtricitabine/tenofovir alafenamide regimen to a boosted protease inhibitor regimen with emtricitabine/tenofovir …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Boosted protease inhibitor + Emtricitabine/Tenofovir Disoproxil Fumarate
• Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Human Immunodeficiency Virus Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2018-11-09